InMed (INM) director granted 3,500 options at $2.1, exp. 2030

InMed Pharmaceuticals (INM) reported a director’s Form 4 for an employee stock option grant of 3,500 options at an exercise price of $2.1 per share on Oct 17, 2025.

Rhea-AI Filing Summary

InMed Pharmaceuticals (INM) reported a director’s Form 4 for an employee stock option grant of 3,500 options at an exercise price of $2.1 per share on Oct 17, 2025. The options expire on Oct 16, 2030.

Vesting is monthly in arrears: 98 options will vest on the 17th of each month for 35 months, and 70 options will vest on Oct 17, 2025, as described in the filing. Following the grant, the reporting person holds 3,500 derivative securities directly.

Insider Trade Summary

Grant/Award: 3,500 shares

Grant/Award 1 txn

Insider Klompas Neil A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	3,500	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 3,500 contracts (Direct)

Footnotes (1)

1. F1. (1) The options were granted on Oct 17, 2025 and will vest monthly, in arrears, as follows: (i) 98 stock options will vest on the 17th day of each month for 35 months, and (ii) 70 stock options will vest on Oct 17, 2025 (the three year anniversary of Grant date).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did InMed (INM) disclose in the Form 4?

A director received 3,500 employee stock options at an exercise price of $2.1 per share on Oct 17, 2025.

What is the vesting schedule for the INM options?

The filing states 98 options vest monthly for 35 months, and 70 options vest on Oct 17, 2025.

When do the INM options expire?

The options expire on Oct 16, 2030.

How many derivative securities are held after this transaction?

The reporting person holds 3,500 derivative securities directly after the reported transaction.

What is the transaction code on the Form 4?

The derivative transaction is coded A (grant or award).

Who is the reporting person for INM in this filing?

The signature is by Eric A Adams, attorney-in-fact for Mr. Neil Klompas.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/21/2025 - 01:58 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klompas Neil A

(Last) (First) (Middle)

C/O INMED PHARMACEUTICALS INC.

1445-885 WEST GEORGIA ST.

(Street)

VANCOUVER A1 V6C3E8

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$2.1	10/17/2025		A		3,500		(1)	10/16/2030	Common shares	3,500	$0.00	3,500	D

Explanation of Responses:

1. (1) The options were granted on Oct 17, 2025 and will vest monthly, in arrears, as follows: (i) 98 stock options will vest on the 17th day of each month for 35 months, and (ii) 70 stock options will vest on Oct 17, 2025 (the three year anniversary of Grant date).

	/s/ Eric A Adams, attorney-in-fact for Mr. Neil Klompas	10/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.